Exploration of the Associations of lncRNA Expression Patterns with Tumor Mutation Burden and Prognosis in Colon Cancer
Chengsheng Ding,Zezhi Shan,Mengcheng Li,Yang Xia,Zhiming Jin
DOI: https://doi.org/10.2147/OTT.S300095
IF: 4
2021-05-01
OncoTargets and Therapy
Abstract:Chengsheng Ding, 1, * Zezhi Shan, 2, 3, * Mengcheng Li, 1 Yang Xia, 1 Zhiming Jin 1 1 Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China; 2 Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; 3 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China *These authors contributed equally to this work Correspondence: Yang Xia; Zhiming Jin Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Yishan Road 600, Shanghai, People's Republic of China Tel +86 15057728772 ; +86 18930177680 Email ; Background: Tumor mutation burden (TMB) is emerging as a new biomarker to monitor the response of cancer patients to immunotherapy. Long non-coding RNAs (lncRNAs) are critical in regulating gene expression and play a significant role in cancer-associated immune responses. However, the association between lncRNA expression patterns and TMB levels and survival outcomes remains unknown in colon cancer. Methods: In colon cancer patients from The Cancer Genome Atlas Program (TCGA), a multi-lncRNAs based classifier for predicting TMB levels was established using the least absolute shrinkage and selection operator (LASSO) method. The association between classifier index and immune-related characteristics of patients was also investigated. Quantitative polymerase chain reaction (qPCR) was used to verify the expression levels of these lncRNAs in normal and CRC cell lines. Results: The multi-lncRNAs based classifier had ability to predict TMB level of patients with accuracy (AUC= 0.70), and the general applicability of this classifier was proved in the validation set (AUC= 0.71) and the pooled set (AUC= 0.70). The classifier index was related to three immune checkpoints (PD1, PD-L1, and CTLA-4), the infiltration level of immune cells, and immune response-related score (IFN-γ score, gene expression profiles (GEP) score, cytolytic activity (CYT) score and MHC score). A nomogram, which integrates classifier and some common clinical information, was able to predict the overall survival of colon cancer patients accurately. Conclusion: LncRNA expression patterns are associated with TMB, which may serve as a classifier to predict the TMB in colon cancer patients. The nomogram could potentially evaluate survival outcomes and provide a reference to better manage colon cancer patients. Keywords: colon cancer, long non-coding RNA, tumor mutation burden, immunotherapy, prognosis Colon cancer is one of the most common malignant tumors in humans. Its incidence and mortality are fourth and second respectively among 36 cancer types worldwide. 1 The incidence of colon cancer is highest in developed countries, but rising in other parts of the world. 2 Early colonoscopy screening and treatment improves the outcome of patients, but the mortality and recurrence rates of colon cancer are not significantly reduced. Indeed, 25–40% of patients who have undergone surgery and chemoradiotherapy experience tumor recurrence with an unsatisfactory prognosis. 3 Studies have illustrated that dysregulation of the immune system can promote the development of cancer. Immunotherapy is rapidly attracting attention in cancer-associated treatment, because it has shown efficacy in some advanced and aggressive cancers. 4–6 At present, tumor-cell PD-L1 expression 7 and tumor-infiltrating lymphocytes 8 have been identified as biomarkers to assist in predicting the response of immunotherapy. However, not all patients show a good response to immunotherapy, with some having no response. 9 It is essential to understand the mechanism of immunotherapy and further explore the new biomarkers for predicting the treatment of immunotherapy better. TMB has emerged as a new promising biomarker for immunotherapy. 10 It has been confirmed that TMB can predict the clinical efficacy of immunotherapy, as a biomarker, in several types of cancers. 11 , 12 For colon cancer, Schrock et al 13 showed that TMB may be an important biomarker for predicting responsiveness of colon cancer patients to immunotherapy; measuring the TMB using whole-exome sequencing (WES) or targeted sequencing panels is -Abstract Truncated-
oncology,biotechnology & applied microbiology